159 related articles for article (PubMed ID: 19776686)
1. Postprandial lipemia in diabetic men during hypolipemic therapy.
Skoczyńska A; Kreczyńska B; Poreba R
Pol Arch Med Wewn; 2009; 119(7-8):461-8. PubMed ID: 19776686
[TBL] [Abstract][Full Text] [Related]
2. Cilostazol, a potent phosphodiesterase type III inhibitor, selectively increases antiatherogenic high-density lipoprotein subclass LpA-I and improves postprandial lipemia in patients with type 2 diabetes mellitus.
Ikewaki K; Mochizuki K; Iwasaki M; Nishide R; Mochizuki S; Tada N
Metabolism; 2002 Oct; 51(10):1348-54. PubMed ID: 12370857
[TBL] [Abstract][Full Text] [Related]
3. Postprandial lipemia and associated metabolic disturbances in healthy and hyperlipemic postmenopausal women.
Pirro M; Lupattelli G; Siepi D; Palumbo B; Roscini AR; Marchesi S; Schillaci G; Mannarino E
Metabolism; 2001 Mar; 50(3):330-4. PubMed ID: 11230787
[TBL] [Abstract][Full Text] [Related]
4. Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study.
Lai CQ; Arnett DK; Corella D; Straka RJ; Tsai MY; Peacock JM; Adiconis X; Parnell LD; Hixson JE; Province MA; Ordovas JM
Arterioscler Thromb Vasc Biol; 2007 Jun; 27(6):1417-25. PubMed ID: 17431185
[TBL] [Abstract][Full Text] [Related]
5. Effect of Taizhi'an capsule combined with Simvastatin on hyperlipidemia in diabetic patients.
Gao F; Hu XF
Chin J Integr Med; 2006 Mar; 12(1):24-8. PubMed ID: 16571279
[TBL] [Abstract][Full Text] [Related]
6. Postprandial hyperlipidemia after a fat loading test in minority adolescents with type 2 diabetes mellitus and obesity.
Umpaichitra V; Banerji MA; Castells S
J Pediatr Endocrinol Metab; 2004 Jun; 17(6):853-64. PubMed ID: 15270403
[TBL] [Abstract][Full Text] [Related]
7. Increased postprandial lipemia in patients with normolipemic peripheral arterial disease.
Lupattelli G; Pasqualini L; Siepi D; Marchesi S; Pirro M; Vaudo G; Ciuffetti G; Mannarino E
Am Heart J; 2002 Apr; 143(4):733-8. PubMed ID: 11923813
[TBL] [Abstract][Full Text] [Related]
8. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
[TBL] [Abstract][Full Text] [Related]
9. Intensive lipid-lowering strategy in patients with diabetes mellitus.
Kanters SD; Algra A; de Bruint TW; Erkelens DW; Banga JD
Diabet Med; 1999 Jun; 16(6):500-8. PubMed ID: 10391399
[TBL] [Abstract][Full Text] [Related]
10. Early improvement of postprandial lipemia after bariatric surgery in obese type 2 diabetic patients.
Griffo E; Nosso G; Lupoli R; Cotugno M; Saldalamacchia G; Vitolo G; Angrisani L; Cutolo PP; Rivellese AA; Capaldo B
Obes Surg; 2014 May; 24(5):765-70. PubMed ID: 24374941
[TBL] [Abstract][Full Text] [Related]
11. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome.
Vega GL; Ma PT; Cater NB; Filipchuk N; Meguro S; Garcia-Garcia AB; Grundy SM
Am J Cardiol; 2003 Apr; 91(8):956-60. PubMed ID: 12686335
[TBL] [Abstract][Full Text] [Related]
12. Simvastatin treatment on postprandial hypertriglyceridemia in type 2 diabetes mellitus patients with combined hyperlipidemia.
Sheu WH; Jeng CY; Lee WJ; Lin SY; Pei D; Chen YT
Metabolism; 2001 Mar; 50(3):355-9. PubMed ID: 11230791
[TBL] [Abstract][Full Text] [Related]
13. Metabolic heterogeneity underlying postprandial lipemia among men with low fasting high density lipoprotein cholesterol concentrations.
Couillard C; Bergeron N; Bergeron J; Pascot A; Mauriège P; Tremblay A; Prud'homme D; Bouchard C; Després JP
J Clin Endocrinol Metab; 2000 Dec; 85(12):4575-82. PubMed ID: 11134111
[TBL] [Abstract][Full Text] [Related]
14. Circadian variation of postprandial lipemia.
Romon M; Le Fur C; Lebel P; Edmé JL; Fruchart JC; Dallongeville J
Am J Clin Nutr; 1997 Apr; 65(4):934-40. PubMed ID: 9094875
[TBL] [Abstract][Full Text] [Related]
15. A reduction of CETP activity, not an increase, is associated with modestly impaired postprandial lipemia and increased HDL-cholesterol in adult asymptomatic women.
Parra ES; Urban A; Panzoldo NB; Nakamura RT; Oliveira R; de Faria EC
Lipids Health Dis; 2011 May; 10():87. PubMed ID: 21609439
[TBL] [Abstract][Full Text] [Related]
16. Impact of corpulence parameters and haemoglobin A1c on metabolic control in type 2 diabetic patients: comparison of apolipoprotein B/A-I ratio with fasting and postprandial conventional lipid ratios.
Diaf M; Khaled BM; Sellam F
Libyan J Med; 2015; 10(1):27400. PubMed ID: 25959906
[TBL] [Abstract][Full Text] [Related]
17. Postprandial amplification of lipoprotein abnormalities in controlled type II diabetic subjects: relationship to postprandial lipemia and C-peptide/glucagon levels.
Cavallero E; Dachet C; Neufcour D; Wirquin E; Mathe D; Jacotot B
Metabolism; 1994 Mar; 43(3):270-8. PubMed ID: 8139473
[TBL] [Abstract][Full Text] [Related]
18. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM
Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751
[TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia.
Ellen RL; McPherson R
Am J Cardiol; 1998 Feb; 81(4A):60B-65B. PubMed ID: 9526816
[TBL] [Abstract][Full Text] [Related]
20. Elevated Levels of Apolipoprotein CIII Increase the Risk of Postprandial Hypertriglyceridemia.
Guan Y; Hou X; Tian P; Ren L; Tang Y; Song A; Zhao J; Gao L; Song G
Front Endocrinol (Lausanne); 2021; 12():646185. PubMed ID: 33967959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
